These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 32692774)

  • 1. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis.
    Kwon BS; Kim Y; Lee SH; Lim SY; Lee YJ; Park JS; Cho YJ; Yoon HI; Lee CT; Lee JH
    PLoS One; 2020; 15(7):e0236109. PubMed ID: 32692774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study.
    Hagiwara E; Suido Y; Asaoka M; Katano T; Okuda R; Sekine A; Kitamura H; Baba T; Komatsu S; Ogura T
    J Infect Chemother; 2019 Dec; 25(12):1026-1030. PubMed ID: 31229376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis.
    Yee D; Valiquette C; Pelletier M; Parisien I; Rocher I; Menzies D
    Am J Respir Crit Care Med; 2003 Jun; 167(11):1472-7. PubMed ID: 12569078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Adverse Drug Reactions to First-Line Anti-Tuberculosis Drugs Using the Korea Adverse Event Reporting System.
    Chung SJ; Byeon SJ; Choi JH
    J Korean Med Sci; 2022 Apr; 37(16):e128. PubMed ID: 35470602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Hyperuricemia Overlooked when Treating Pediatric Tuberculosis Patients with Pyrazinamide?
    Şişmanlar T; Aslan AT; Budakoğlu I
    J Trop Pediatr; 2015 Oct; 61(5):351-6. PubMed ID: 26136257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
    Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
    Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes of pyrazinamide-monoresistant Mycobacterium tuberculosis in Quebec.
    Yee DP; Menzies D; Brassard P
    Int J Tuberc Lung Dis; 2012 May; 16(5):604-9. PubMed ID: 22409887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
    Lin HS; Cheng CW; Lin MS; Chou YL; Chang PJ; Lin JC; Ye JJ
    Clin Interv Aging; 2016; 11():299-306. PubMed ID: 27042029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.
    Ngabonziza JCS; Diallo AB; Tagliani E; Diarra B; Kadanga AE; Togo ACG; Thiam A; de Rijk WB; Alagna R; Houeto S; Ba F; Dagnra AY; Ivan E; Affolabi D; Schwoebel V; Trebucq A; de Jong BC; Rigouts L; Daneau G;
    PLoS One; 2017; 12(10):e0187211. PubMed ID: 29088294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
    Marra F; Marra CA; Bruchet N; Richardson K; Moadebi S; Elwood RK; Fitzgerald JM
    Int J Tuberc Lung Dis; 2007 Aug; 11(8):868-75. PubMed ID: 17705952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence rate and time to serious adverse events among rifampicin resistant tuberculosis patients in Georgia treated with new and repurposed anti-tuberculosis drugs, 2016-2018.
    Buziashvili M; Davtyan H; Sereda Y; Denisiuk O; Gozalov O; Lomtadze N; Hovhannesyan A
    Monaldi Arch Chest Dis; 2021 Jan; 91(1):. PubMed ID: 33470083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
    Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
    Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis.
    Schaberg T; Rebhan K; Lode H
    Eur Respir J; 1996 Oct; 9(10):2026-30. PubMed ID: 8902462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
    Okumura M; Sasaki Y; Yoshiyama T; Matsuda S; Osawa T; Morimoto K; Yanai H; Kurasima A; Ogata H; Gotoh H
    Kekkaku; 2015 Oct; 90(10):665-70. PubMed ID: 26821395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
    BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs.
    Suzuki Y; Miwa S; Shirai M; Ohba H; Murakami M; Fujita K; Suda T; Nakamura H; Hayakawa H; Chida K
    Chest; 2008 Nov; 134(5):1027-1032. PubMed ID: 18583516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.